Docs never want Afrezza; they want Valtessa. Drug reps don't waste their time trying to peddle something docs don't need/want/are really reluctant to try. AFREZZA was DOA.
lurker, are you saying that Berrens is trying to suppress the price to buy time to see if FDA will back ZS9? For what purpose - so that someone can accumulate shares of Valtessa at a reduced price?
LOL! A quick review of the price action while we are at it: When FD approved Valtessa with the black box, stock dropped $5, and lost $2 more right before approval (a leak I'm sure). When Astra bought ZS the stock went up $2. So now that the black box looks like it will be neutralized AND there are four or more parties looking to buy it, the price should go back up in short order!
Note to drug developers: Stop renaming your drugs for post FDA acceptance. Docs follow clinical trials for drugs in development. Unless the drug will be patient driven, there is no need to come up with a more "marketable" name.
Jet,As someone whose mother died of metastatic pancreatic cancer within 3 months of diagnosis, and whose wife's mother also died from the same illness within 9 months of diagnosis, I think this preliminary data looks fantastic. Most people unfamiliar with the ravages of pancreatic cancer don't realize that to date, after decades of drug trials, nothing has moved the needle on pancreatic cancer. Once diagnosed, a patient is told they have between 3-11 months to live, unless surgery is possible, and even then the outcome is bleak. While the percentages are not reliable at this point, (42% versus 23%), that still represents an 82% improvement with anecdotal data. While not being able to quantify anything, clearly something very positive is happening here. and the fact that they got a complete response - even one - is phenomenal in this disease. If any oncologists are on this board, please weigh in.
It's baffling that this company is sitting at a market cap of $530 mill net of cash and debt. 1x the most conservative sales projection.
I agree lurker. The one piece of data that we don't know (as far as I know) is how many trial patients in the ZS arms had systolic BP counts I the 140-180 range, which is normally considered hypertensive. The FDA, however, should have that data.
MKND was DOA (dead on arrival) IMHO. RLYP is in a different ball park. But I agree the shorts were pummeled on PCYC, as they were with ITMN, rcpt, and just about every other buyout.
Most BO rumors do not have the specificity that RLYP has had: two specific prices ($46) and four specific companies mentioned. I put that above 50-50. This feels a lot like ITMN or RCPT.
I also recommend this medical review of the data between ZS9 and Valtessa
It will have been a month and a week on this Monday morning since rumors started flying about a Merck bid, followed by rumors of other bids and multiple companies interested. I think the time is up - 7 am Monday sounds about right for a buyout announcement at $52-$55 a share. If it happens, cheers!
on the other hand, T/A can often indicate a move before it happens from news, because there is almost always a few who knows the news before the rest of us do, and T/A picks that up.
In researching the investigative unit of the SEC, the first line of investigation is usually an informal one. Only when the SEC has enough evidence that makes it likely that illegal trading has occurred is a subpoena issued to open a formal investigation. So that means they have their eyes on one or more folks outside the company who have been manipulating the stock (probably short), causing the price drop in November that took the price from $14 to nearly $3. To which I say, round 'em up, lock 'em up, and throw away the key!